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PURPOSE. To limit corneal damage and potential loss of vision, bacterial keratitis must be
treated aggressively. Innovation in antimicrobials is required due to the need for empirical
treatment and the rapid emergence of bacterial resistance. Designed host defense peptides
(dHDPs) are synthetic analogues of naturally occurring HDPs, which provide defense against
invading pathogens. This study investigates the use of novel dHDPs for the treatment of
bacterial keratitis.
METHODS. The minimum inhibitory concentrations (MICs) were determined for dHDPs on
both Gram-positive and -negative bacteria. The minimum biofilm eradication concentrations
(MBEC) and in vitro time-kill assays were determined. The most active dHDP, RP444, was
evaluated for propensity to induce drug resistance and therapeutic benefit in a murine
Pseudomonas aeruginosa keratitis model.
RESULTS. Designed HDPs were bactericidal with MICs ranging from 2 to >64 lg/mL and MBEC
ranging from 6 to 750 lg/mL. In time-kill assays, dHDPs were able to rapidly reduce bacterial
counts upon contact with as little as 2 lg/mL. RP444 did not induce resistance after repeated
exposure of P. aeruginosa to subinhibitory concentrations. RP444 demonstrated significant
efficacy in a murine model of bacterial keratitis as evidenced by a significant dose-dependent
decrease in ocular clinical scores, a significantly reduced bacterial load, and substantially
decreased inflammatory cell infiltrates.
CONCLUSIONS. Innovative dHDPs demonstrated potent antimicrobial activity, possess a limited
potential for development of resistance, and reduced the severity of murine P. aeruginosa
keratitis. These studies demonstrate that a novel dHDP may have potential to treat patients
with sight-threatening bacterial keratitis.
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Bacterial keratitis is an aggressive corneal infection that,without prompt and effective treatment, can lead to
perforation of the cornea and blindness.1 In the United States,
there are approximately 30,000 patients annually with these
infections, with contact lens wear as the prime risk factor.
Bacterial keratitis is presently treated with antibiotics, partic-
ularly fluoroquinolones; however, innovation in antimicrobials
is needed due to the rapid emergence of bacterial resistance
and pathogen resilience to biofilm formation.2–4
Pathogens causing bacterial keratitis include both Gram-
positive and -negative bacteria. Gram-positive causative patho-
gens include Enterococcus faecium,5 Staphylococcus aureus
(including methicillin-resistant Staphylococcus aureus
[MRSA]),6 Staphylococcus epidermidis,6 and Streptococcus
pneumonia.6 Gram-negative causative pathogens include
Pseudomonas aeruginosa,6 Enterobacter aerogenes,7 and
Acinetobacter baumanii.8 The most frequent pathogen in
bacterial keratitis associated with contact lens wear is Gram-
negative P. aeruginosa while for non–contact lens–related
disease the Gram-positive bacterium S. aureus predomi-
nates.9,10
Pathogens that cause bacterial keratitis can become ex-
tremely resilient to traditional antibiotic treatment due to
biofilm formation. Bacteria within biofilms are 20 to 1000 times
less sensitive to antibiotics than their planktonic counter-
parts,11 as they are physically protected from antibiotics and
the host’s immune system. Hence the imperative need to find
efficacious agents that are able to target biofilms and eradicate
disease-causing bacteria. The increasing emergence of antibiot-
ic resistance also highlights the need for innovative alternatives
that provide rapid and complete microbicidal activity with
minimal safety-related effects while exhibiting limited suscep-
tibility to mechanisms of microbial resistance.
Designed host defense peptides (dHDPs) are synthetic
peptides that are chemically derived from naturally occurring
HDPs (also referred to as antimicrobial peptides), which
provide the first line of defense against invading pathogens.12
HDPs possess an amphipathic a-helix or b-sheet structure and a
net positive charge. These features are crucial as the peptides
generally act as antimicrobial agents through electrostatic
interactions with the microbial membrane, thereby perturbing
the barrier function of these membranes. HDPs are effective
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against Gram-positive and -negative bacteria.13,14 The direct
killing of bacteria via perturbation of the cell membrane infers
a reduced likelihood of inducing bacterial resistance, a critical
key in fighting antibiotic-resistant pathogens.15
There is an urgent and profound need for the design and
clinical development of dHDPs to treat sight-threatening
infectious keratitis. Here, 11 novel dHDPs were evaluated for
their bactericidal effectiveness against isolates and biofilm
cultures of both Gram-positive and -negative bacteria, and
against drug-resistant MRSA and P. aeruginosa. The most
promising of these novel peptides, RP444, was evaluated for
potential to induce resistance and efficacy in a murine model
of P. aeruginosa keratitis.
METHODS
Designed Host Defense Peptides
Eleven dHDPs, whose amino acid sequences are depicted in
Table 1, were synthesized via traditional solid phase synthesis
(CSBio, Menlo Park, CA, USA). The discovery and identification
of the bactericidal cecropins and magainins and their role in
providing ‘‘freedom from infection’’ provided the structural
basis and amphipathic properties upon which these dHDPs
were designed.16–19 The peptide sequences include use of
nonnatural amino acids, not encoded by the Universal Genetic
Code, and the specific replacement of lysine with ornithine,
which has been shown to increase antibacterial activity while
also enhancing proteolytic stability.20–21
Bacterial Strains
Bacterial strains were obtained from American Type Culture
Collection (ATCC, Manassas, VA, USA). The Gram-positive
bacterial strains included Enterococcus faecium ATCC 700221
(E. faecium 700221), methicillin-resistant Staphylococcus
aureus ATCC 33591 (MRSA 33591), Staphylococcus epidermi-
dis ATCC 51625 (S. epidermis 51625), Streptococcus pneumo-
niae ATCC 49619 (S . pneumoniae 49619), and
Staphylococcus aureus ATCC 49525 (Wright).
The Gram-negative bacterial strains tested were Enterobac-
ter aerogenes ATCC 13048 (E. aerogenes 13048), Acineto-
bacter baumannii Bouvet and Grimont ATCC 17978D-5 (A.
baumannii 17978D-5), Pseudomonas aeruginosa ATCC
19660 (P. aeruginosa 19660), and Pseudomonas aeruginosa
ATCC 27853 (P. aeruginosa 27853).
The bioluminescence strains, P. aeruginosa 19660 trans-
fected with the Xen5 luciferase gene (here termed P.
aeruginosa 19660_Xen5), and Staphylococcus aureus ATCC
49525 (Wright) transfected with the Xen36 luciferase gene (S.
aureus 49525_Xen36), were obtained from PerkinElmer
(Hopkinton, MA, USA).22,23
In Vitro Bactericidal Activity
The minimum inhibitory concentrations (MICs) of dHDPs were
determined by broth microdilution methods approved by the
Clinical and Laboratory Standards Institute.24 The minimum
biofilm eradication concentrations (MBECs) were determined
using the MBEC Assay system (Innovotech, Edmonton, AB,
Canada).25 Briefly, the bacteria are grown on 96-well plates
with pegs on the lid filled with growth medium enabling
biofilm formation on the pegs. The reduction in viable bacteria
living in biofilm after exposure to the dHDPs was calculated as
the difference between the viable colony forming units (CFU)
on the control pegs and those in the treated pegs. The MBEC
values for the dHDPs are higher than the corresponding MIC
values; thus any bacteria in a biofilm that were shed or
dissipated during the biofilm assay have been eradicated by the
MBEC level of dHDP.
Antibiotic Resistance Profiling
Subinhibitory concentrations of RP444 and gentamicin were
incubated with P. aeruginosa 27853 for 24 hours. The bacteria
that showed growth in the highest concentration were
repassaged in fresh dilutions containing sub-MIC levels of
RP444 or gentamicin. The MIC was redetermined at each time
point, and this was repeated for 21 consecutive passages.
Time-Kill Bactericidal Activity
Noninvasive and real-time monitoring of dHDP bactericidal
activity was performed using bioluminescent strains of P.
aeruginosa and S. aureus.26,27 Cultures of P. aeruginosa
19660_Xen5 and S. aureus 49525_Xen36 were made from a
single colony, which was inoculated into 5 mL sterile lysogeny
broth (LB). Tubes were incubated at 378C overnight with
agitation. Cultures were diluted 1:10 into fresh LB and
incubated at 378C for 2 hours to achieve mid-logarithmic
growth. Optical density measurements (OD, 600 nm) were
performed on the bacterial cultures, which were then adjusted
to 13107 CFU/mL. Bacterial suspensions (100 lL) were plated
in 96-well black-walled plates. The candidate dHDPs were 2-
fold serially diluted from 128 lg/mL in LB. Each concentration
was done in triplicate, with the final volume being 200 lL.
Imaging was performed at select times after the addition of the
dHDP, and compared to concurrently run positive control
antibiotics, tobramycin and vancomycin, using an IVIS Lumina
imaging system (Caliper Life Sciences, Inc., Hopkinton, MA,
USA). For imaging, the 96-well plate was positioned on the
stage (12.5-cm field of view), with an open emission filter,
binning of 4, and f-stop 1. Photons were counted for 30
seconds, and data analysis was performed using the Living-
Image software program (version 4.3, Caliper Life Sciences,
Inc.).
Animals
All animals received care in compliance with the Guide for the
Care and Use of Laboratory Animals (National Institutes of
Health Publication, 1996) and the ARVO Statement for the Use
of Animals in Ophthalmic and Vision Research. All studies were
approved by the Institutional Animal Care and Use Committee
at the University of Houston. C57BL/6 mice, 9 to 13 weeks,
were obtained from The Jackson Laboratory (Bar Harbor, ME,
USA). General anesthesia consisted of an intraperitoneal
TABLE 1. Amino Acid Sequences of the dHDPs Evaluated in This Study
dHDP dHDP Sequence
RP435 MGFKLRAKIKVRLRAKIKL
RP436 CVOLFPVOLFPC; disulfide bond C-1 to C-12
RP437 CKLRFRGPGRIKVRLC; disulfide bond C-1 to C-12
RP438 (CPGFAKKFAKKFKKFAKKFAKFAFAF)2
RP439 KIRAKLCLGRFCIRAKLR; disulfide bond C-7 to C-12
RP440 KKKPKPPYLPKPKPPPFFPPKLPPKI
RP441 (FAFAFKAFKKAFKKFKKAFKKAFGPC)2
RP442 FAFAFAFKKAFKKFKKAFKKAF
RP443 FAFAFOAFOOAFOOFOOAFOOAF
RP444 FAOOFAOOFOOFAOOFAOFAFAF
RP445 FAKKFAKKFKKFAKKFAFAFAF
A, alanine; C, cysteine; F, phenylalanine; I, isoleucine; K, lysine; L,
leucine; M, methionine; O, ornithine; P, proline; R, arginine; V, valine.
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injection of ketamine 100 mg/kg and xylazine 10 mg/kg
(Vedco, Inc., St. Joseph, MO, USA).
In Vivo Corneal Epithelial Wound Healing
Rapid clearance occurs following topical ocular application, due
in part to test agent drainage, blinking (every 5 minutes in mice),
tear film, and tear film turnover.28 Therefore, in consideration of
in vitro to in vivo dosing translation, low, mid, and high doses of
2, 64, and 640 lg/mL were evaluated in a murine model of
corneal wound healing. Corneal epithelial scrape wounds (2-
mm diameter) were made with an Algerbrush under a dissecting
microscope in the right eye.29,30 Immediately following wound
creation, 5 lL RP444 (2, 64, or 640 lg/mL) or vehicle (PBS) was
applied. Topical application of the drops was repeated 5
minutes later, and then again at 6, 12, and 18 hours post
wound. Corneal wound areas were assessed by staining with 1.5
lL 1% sodium fluorescein (Sigma-Aldrich Corp., St. Louis, MO,
USA) every 6 hours until wound closure (24 hours) and images
captured with an Olympus SZX16 stereomicroscope (Center
Valley, PA, USA). Wound areas were outlined and measured with
ImageJ software (https://imagej.nih.gov/ij/; provided in the
public domain by the National Institutes of Health, Bethesda,
MD, USA), and expressed as a percentage of the original wound
area, at 0 hours.30 Data were analyzed using 2-way repeated
measures ANOVA with Bonferroni’s test for multiple compari-
sons, with P < 0.05 considered significant.
Murine P. aeruginosa Keratitis Model
Scarified eyes were infected with 1 3 105 CFU P. aeruginosa
ATCC 19660 as outlined by Kolar and colleagues,31 and dosed
with 5 lL PBS or 2, 64, or 640 lg/mL RP444, beginning 8 hours
post infection and continuing every 8 hours thereafter for 4
days. The clinical progression of infection was evaluated by
capturing digital images using a slit-lamp biomicroscope
equipped with a camera module CM 01 (Haag-Streit USA,
Mason, OH, USA) on days 1, 3, and 5 post infection. The
corneal infection was graded using a clinical scale of 0 to 4: 0,
clear or slight opacity, partially covering the pupil; þ1, slight
opacity, fully covering the cornea; þ2, dense opacity, partially
or fully covering the pupil;þ3, dense opacity fully covering the
cornea; and þ4, corneal perforation or phthisis.
At days 1, 3, and 5 post infection, corneas from infected
eyes of 4 to 10 mice per group were harvested, and two
corneas were pooled in 200 lL sterile PBS, generating two to
five independent samples. The corneas were homogenized and
then briefly sonicated. A 10-lL aliquot of the homogenate was
diluted in sterile PBS and 10-fold serial dilutions were plated in
duplicate onto Pseudomonas isolation agar plates. The plates
were incubated overnight at 378C and CFU counted.
The remainder of the homogenate was processed to
quantitate the number of infiltrating inflammatory cells by
myeloperoxidase (MPO) activity, a standard and well-estab-
lished method in the study of infectious keratitis.32,33 Corneal
homogenate (90 lL) was added to hexadecyltrimethylammo-
nium bromide at a final concentration of 0.5% wt/vol in 50 mM
phosphate buffer (pH 6.0). Samples were then freeze-thawed
three times and centrifuged at 8,000g for 20 minutes at 48C.
Ten microliters supernatant was pipetted in triplicate into a
microtiter plate and the reaction initiated by the addition of 90
lL 0.0167% (wt/vol) o-dianisidine dihydrochloride and 0.002%
(vol/vol) H2O2 in PBS. The absorbance was measured for up to
3 hours at 450 nm. A standard curve was generated using
purified MPO (Calbiochem, San Diego, CA, USA) on the same
plate. Results were expressed as relative units of MPO activity
per cornea (one MPO unit is proportional to 23105 infiltrating
neutrophils).
Data are expressed as mean 6 standard error (SE).
Comparisons were performed using a 1-way analysis of
variance (ANOVA) followed by a post hoc Dunnett’s test. A P
value < 0.05 was considered statistically significant.
RESULTS
dHDPs Exhibit Broad-Spectrum Bactericidal
Activity
Eleven dHDPs were screened for their bactericidal effective-
ness against four strains of Gram-positive and -negative
bacteria, representing the most common keratitis pathogens,
using the MIC assay (Table 2). RP438, RP442, RP443, and
RP444 (shaded columns) were the most active peptides against
both Gram-positive and -negative bacterial species and were
selected for additional bactericidal screening.
dHDPs Are Active Against Gram-Negative and
-Positive Biofilms
In addition to inhibiting planktonic growth, the MBEC values
demonstrate effective eradication of both Gram-positive and
-negative bacteria in their biofilm form (Table 3).
TABLE 2. Minimum Inhibitory Concentrations (MICs, lg/mL) Against Gram-Positive and -Negative Bacteria
dHDPs
RP435 RP436 RP437 RP438* RP439 RP440 RP441 RP442* RP443* RP444* RP445
Gram-Positive Bacteria
E. faecium 700221 >64 >64 >64 16 16 >64 >64 8 8 32 32
MRSA 33591 >64 >64 >64 32 64 >64 >64 16 16 16 >64
S. epidermidis 51625 4 >64 >64 16 4 >64 64 4 1 4 8
S. pneumoniae 49619 >64 >64 >64 32 64 >64 >64 64 16 64 16
Gram-Negative Bacteria
E. aerogenes 13048 >64 >64 >64 32 64 >64 >64 >64 >64 8 32
A. baumannii 17978D-5 >64 >64 >64 16 64 >64 >64 2 4 2 32
P. aeruginosa 19660 >64 >64 >64 32 64 >64 >64 >64 64 32 32
P. aeruginosa 27853 >64 >64 >64 32 64 >64 >64 >64 16 8 32
Minimum inhibitory concentration (MIC) is the lowest concentration of dHDP that shows no growth after a 24-hour incubation. Data represent
the mean of three replicates from three independent experiments.
* RP438, RP442, RP443, and RP444 columns represent the most potent broad-spectrum dHDPs.
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dHDPs Rapidly Eradicate P. aeruginosa and S.
aureus in In Vitro Time-Kill Assays
The immediate concentration-dependent bacterial eradication
by RP438, RP442, RP443, RP444, tobramycin, and vancomycin
on P. aeruginosa 19660_Xen5 is shown in Figure 1. RP444
killed P. aeruginosa immediately in a concentration-dependent
manner, suggesting that RP444 exerts its bactericidal activity
by disrupting membrane function (Fig. 1). In contrast, all other
evaluated dHDPs, including tobramycin, an aminoglycoside
that disrupts cell membranes and protein synthesis in Gram-
negative bacteria, and vancomycin, a bactericide that acts by
inhibiting cell wall synthesis in Gram-positive bacteria,
exhibited no trace of antibacterial activity upon direct
exposure.
P. aeruginosa, as illustrated in Figure 2, was killed by all
evaluated dHDPs following 60 minutes of exposure. The
order of bactericidal effectiveness was RP444 followed by
RP443, with RP442 and RP438 being equipotent. The striking
immediate bactericidal activity of the dHDPs relates to direct
electrostatic interaction with the bacterial walls. As antici-
pated, due to their respective modes of action, vancomycin
showed no evidence of bactericidal activity during this short
incubation time period (2 hours), with tobramycin exhibiting
bactericidal effects at 60 minutes. The concentration-depen-
dent time-kill evaluation of RP444 on P. aeruginosa
19660_Xen5 is displayed in Figure 3. P. aeruginosa was
killed by RP444 within 30 minutes with as little as 2 lg/mL
peptide.
The bactericidal activities of dHDPs, tobramycin, and
vancomycin against S. aureus 49525_Xen36 are depicted in
Figure 4 following 30 minutes’ incubation time. RP442, RP443,
and RP444 were effective at killing S. aureus, while neither
tobramycin nor vancomycin exhibited any bactericidal effect
during this exposure time.
P. aeruginosa Did Not Develop Resistance Against
RP444
P. aeruginosa did not become resistant to RP444 after 21
rounds of selection whereas gentamicin did, as evidenced by
growing at 1024 times the MIC after 21 days (Fig. 5).
RP444 Did Not Impede In Vivo Corneal Epithelial
Wound Healing
RP444 did not affect corneal epithelial wound healing in an in
vivo murine wound healing model, with results obtained from
two independent experiments (Fig. 6). No statistically signif-
icant difference in closure at 24 hours following topical ocular
RP444 administration was observed. Hence, risks associated
with delayed healing would not be anticipated following
RP444 application.
RP444 Reduced the Severity of Murine P.
aeruginosa Keratitis
RP444 demonstrated significant in vivo activity in reducing
clinical scores and corneal opacity in a P. aeruginosa model of
bacterial keratitis (Fig. 7). Clinical scores were not different
among the groups on day 1 post infection. However, scores
were lower in treated animals on day 3 post infection, although
they were not significantly different (data not shown). A dose-
dependent decrease in ocular clinical scores was observed on
day 5 post infection with scores of 2.56 6 0.176, 1.80 6
0.374, 1.56 6 0.176, and 1.20 6 0.200 obtained for the PBS
control and 2, 64, and 640 lg/mL groups, respectively. All
RP444-treated groups yielded lower clinical scores compared
to the control group, with the data for the 64 and 640 lg/mL
RP444-treated groups significantly less than for the control
group (P < 0.001 and 0.0001 for 64 and 640 lg/mL RP444,
respectively).
RP444 Reduced Bacterial Burden in Murine P.
aeruginosa Keratitis
RP444 demonstrated statistically significant in vivo efficacy in
reducing corneal bacterial burden in the murine P. aerugi-
nosa model of bacterial keratitis. The number of viable
bacteria recovered from the 64 and 640 lg/mL peptide-
treated groups on day 3 (P < 0.001 and P < 0.001) and day 5
post infection (P < 0.01 and P < 0.001; Fig. 8A) was
significantly lower than from the PBS-treated control. There
was no difference in the number of viable bacteria between
the control and 2 lg/mL peptide-treated groups at all time
points.
TABLE 3. Minimum Biofilm Eradication Concentration (MBECs, lg/
mL) Values Against Gram-Positive and -Negative Biofilm Bacteria
dHDPs
RP438 RP442 RP443 RP444
Gram-positive bacteria
MRSA 33591 94 47 24 47
S. epidermis 51625 94 47 12 47
Gram-negative bacteria
A. baumannii 17978D-5 47 6 12 12
P. aeruginosa 27853 375 750 188 188
Minimum biofilm eradication concentration (MBEC) is the lowest
concentration needed to kill biofilm bacteria. Data represent the mean
of three replicates from three independent experiments.
FIGURE 1. RP444 kills P. aeruginosa upon direct application. RP438,
RP442, RP443, RP444, tobramycin, and vancomycin were applied to P.
aeruginosa 19660_Xen5, and bactericidal effectiveness was assessed
immediately after direct contact at time zero. The bioluminescence of
viable bacteria was evaluated noninvasively with an IVIS Lumina
bioimaging system. Data represent the mean 6 SE of triplicate
replicates from two independent experiments. For some points, the
error bars are shorter than the height of the symbols.
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RP444 Reduced Inflammatory Cell Infiltration in
Murine P. aeruginosa Keratitis
RP444 demonstrated significant in vivo efficacy in reducing
inflammatory cell infiltration in the P. aeruginosa model of
bacterial keratitis (Fig. 8B). At day 1 post infection there was no
significant difference between the vehicle- and RP444-treated
corneas at any of the three concentrations. At day 3 post
infection, MPO activity in corneas treated with 2, 64, or 640
lg/mL RP444 was dose-dependently lower than for treatment
with the PBS vehicle (P < 0.05, P < 0.001, and P < 0.001 for 2,
64, and 640 lg/mL RP444, respectively). At day 5 post
infection, MPO activity was lower in corneas treated with
RP444, reaching statistical significance in the 64 and 640 lg/
mL RP444-treated groups (P < 0.001).
DISCUSSION
Designed host defense peptides are synthetic analogues of
naturally occurring HDPs that provide the first line of defense
against invading pathogens.34 Endogenous HDPs were initially
recognized for their microbiocidal activity but are now
recognized as critical immune effector and regulatory mole-
cules that guard against infections and support healing, while
FIGURE 2. dHDPs exhibiting concentration-dependent killing of P. aeruginosa. The bactericidal effectiveness of RP438, RP442, RP443, RP444,
tobramycin, and vancomycin was evaluated against P. aeruginosa 19660_Xen5 following 0, 30, 60, and 120 minutes’ incubation. The
bioluminescence of viable cells was quantitated noninvasively with an IVIS Lumina bioimaging system. Data represent the mean 6 SE of triplicate
replicates from two independent experiments. For some points, the error bars are shorter than the height of the symbols.
FIGURE 3. RP444 quickly kills P. aeruginosa in a concentration-
dependent manner. Time-kill and concentration-dependent killing of P.
aeruginosa 19660_Xen5 by RP444 was evaluated. The biolumines-
cence of viable cells was quantitated with an IVIS Lumina imaging
system. Data represent the mean 6 SE of triplicate replicates from two
independent experiments. For some points, the error bars are shorter
than the height of the symbols.
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suppressing inflammation.13,35,36 To date, the experimental
therapeutic benefit of HDPs for bacterial keratitis has been
mixed. COL-1, a 20–amino acid peptide, at doses up to 50 lg/
mL, was investigated in a rabbit model of P. aeruginosa
keratitis.37 COL-1 did not exhibit antimicrobial activity and
induced corneal toxicity.37 The COL-1 dosing regimen entailed
administration beginning 12 to 14 hours post infection and
then every 15 minutes for the first hour, followed by dosing
every hour for the next 9 hours. Then on days 2 through 4,
dosing was every hour for 10 hours. More recently, the topical
application of OH-CATH30 was shown to be efficacious in a
rabbit de-epithelialization P. aeruginosa keratitis model when
administered as 10 hourly doses of 1 mg/mL, 8 hours post
infection.38 Additionally, an amphibian skin-derived esculentin,
Esc-1a(1-21)NH2, was shown to reduce bacterial load and
improve ocular clinical scores in a murine P. aeruginosa-
induced keratitis model following topical administration at 88
lg/mL at 5 hours post infection and continuing three times a
day for 5 days.39
Here, 11 dHDPs were shown to possess broad-spectrum
antimicrobial activity following assessment of bactericidal
effectiveness against isolates of both Gram-positive and
-negative bacteria, and against drug-resistant pathogens (MRSA
and P. aeruginosa). Empirical antimicrobial management of
ocular infections is needed so an antimicrobial treatment
possessing broad-spectrum activity with activity against
recalcitrant biofilm is critical to limit the potential threat of
corneal damage and vision loss.1,6 Four of these dHDPs (RP438,
RP442, RP443, and RP444) were evaluated in additional in
vitro assays that demonstrated their effectiveness in eradicating
bacteria in biofilm. Biofilms are sophisticated colonies of
microorganisms encased in a dense extracellular matrix
enabling the bacteria to be extremely virulent and resilient,
hence the imperative need to find efficacious agents that are
able to encroach biofilms and kill bacteria.40 Preclinical studies
indicate that mature biofilms are a common resilient feature of
keratitis and need to be considered when developing
therapeutic agents.41
Bacterial eradication should7 be the primary goal of
antibiotic treatment, with bacterial load the main determinant
of therapeutic outcome.42 Rapid, precise healing at the corneal
surface is critical for restoration of the cornea’s important
protective and optical functions. Additionally, the rapid
elimination of the infective organism should limit the
emergence of resistance and the spread of infection. MIC and
MBEC values, though useful for bacterial screening, provide no
information on the time course of antimicrobial activity or the
distinction between bacteriostatic and bactericidal mecha-
nisms of action. Antimicrobial agents that disrupt cell
membranes or interfere with essential enzyme function are
likely to be bactericidal, whereas agents that inhibit ribosomal
FIGURE 4. RP442, RP443, and RP444 exhibit antibacterial activity
against S. aureus. The concentration-dependent profile of dHDPs,
tobramycin, and vancomycin against S. aureus 49525_Xen36
following 30 minutes. The bioluminescence of viable cells was
quantitated with an IVIS Lumina imaging system. Data represent the
mean 6 SE of triplicate replicates from two independent experi-
ments. For some points, the error bars are shorter than the height of
the symbols.
FIGURE 5. P. aeruginosa did not develop resistance against RP444.
After 21 days of culturing P. aeruginosa ATCC 27853 with gentamicin,
resistance was observed as 1024 times the MIC was needed for growth
to occur whereas no resistance was observed with RP444. Assay was
performed in duplicate; means are shown.
FIGURE 6. RP444 treatment does not affect in vivo wound closure.
Mice were wounded and treated with vehicle (PBS) or RP444 (2, 64,
or 640 lg/mL) every 6 hours for 24 hours. Corneal wound areas were
assessed by fluorescein staining every 6 hours. The percentage of
wound remaining open was determined by comparison to the original
wound area. Data represent mean 6 SE and were analyzed with 2-way
repeated measures ANOVA and Bonferroni’s correction for multiple
comparisons. *P < 0.05; statistically significant difference between
vehicle and RP444 640 lg/mL treatment; n ¼ 7–10 mice/group.
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function are most likely bacteriostatic. An innovative time-kill
assay using P. aeruginosa and S. aureus transfected with
luciferase reporter genes was utilized to enable real-time
evaluation of the effects of dHDPs and the antimicrobial agents
tobramycin and vancomycin on bacteria viability.
The in vitro time-kill assays demonstrated that RP444
quickly killed bacteria, particularly P. aeruginosa, at relatively
low doses (2 lg/mL) that were not cytotoxic to ocular cells as
evidenced in the corneal epithelial wound study, which
utilized repeat dosing of RP444 concentrations up to 640 lg/
mL. The rapid destruction of the bacterial cells by potent
broad-spectrum topical anti-infectives, thought to be primar-
ily due to peptide–lipid interactions, imply a theoretical
reduced likelihood of developing bacterial resistance.6,7 This
was supported by RP444’s lack of induction of resistance
following repeated incubation with P. aeruginosa. Given the
favorable therapeutic index with selective disruption of
bacterial cells over the in vivo murine corneal epithelial
cells, and its rapid bactericidal activity, RP444 was selected
for evaluation of its therapeutic potential in a murine model
of bacterial keratitis.
The topical application of 64 and 640 lg/mL RP444, at a
dosing volume of 5 lL, reduced the severity of murine P.
aeruginosa keratitis. This is reflected in an improved clinical
score, reduced recovery of viable bacteria, and reduced
immune cell infiltration.
In summary, a topically applied antimicrobial peptide,
RP444, has been identified that exhibits rapid bactericidal
activity, broad-spectrum effectiveness against isolates and
biofilm, selective targeting of bacterial cell walls, and reduced
FIGURE 7. RP444 significantly reduced ocular disease in a murine P. aeruginosa keratitis model. Data are mean clinical scores 6 SE from two
independent experiments 5 days post infection with n¼ 9, 5, 9, and 10 mice for 0, 2, 64, and 640 lg/mL groups, respectively. **P < 0.01 and
***P < 0.001; statistically significant difference among control and RP444 treated. The right side of the figure shows representative
photographs of the treated infected right eyes compared to the uninfected left eye, illustrating a reduction in pathology (opacity) with RP444
treatment.
FIGURE 8. RP444 topical treatment reduces bacterial load and inflammatory cell infiltration in a murine P. aeruginosa keratitis model. (A) Viable
bacterial counts in infected corneas treated with RP444 at 64 and 640 lg/mL were significantly lower than in PBS-treated animals at days 3 and 5
post infection. (B) A dose-dependent decrease in inflammatory cell infiltration, as measured by myeloperoxidase (MPO) activity, was observed in
RP444-treated animals at days 3 and 5 post infection. Data are from three to six independent samples generated in one (2 and 640 lg/mL) or two
experiments (64 lg/mL). Statistical significance was *P < 0.5, **P < 0.01, and ***P < 0.001.
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likelihood of developing bacterial resistance. Further preclin-
ical evaluation is under way to evaluate RP444 as a potential
therapeutic for the treatment of sight-threatening bacterial
keratitis.
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